AB SCIENCE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.936 EUR | +2.76% |
|
-1.63% | -45.54% |
| 04/04 | AB Science's Reconsideration Request for ALS Treatment Granted Eligibility in Canada | MT |
| 03/04 | AB Science: reconsideration possible for masitinib in ALS | CF |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Specialty & Advanced Pharmaceuticals
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 106M | - | - | - | - | - | |
| 70.44B | ||||||
| 8.94B | ||||||
| 4.75B | ||||||
| 4.5B | - | - | ||||
| 3.85B |
- Stock Market
- Equities
- AB Stock
- Charts AB Science
- Sector Chart
